FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Shepherd

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Geographic Areas

Scotland

Co-author Network

Publications

TOP 3
Peter W Macfarlane; Heather Murray; Naveed Sattar; David J Stott; Ian Ford; Brendan Buckley; J Wouter Jukema; Rudi G J Westendorp; James Shepherd
The incidence and risk factors for new onset atrial fibrillation in the PROSPER study.
Bo Fan; Ying Lu; Harry K Genant; Thomas Fuerst; James Shepherd
Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems?
David Preiss; Paul Welsh; Heather M Murray; James Shepherd; Chris Packard; Peter Macfarlane; Stuart M Cobbe; Ian Ford; Naveed Sattar
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Shepherd (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Peter W Macfarlane; Heather Murray; Naveed Sattar; David J Stott; Ian Ford; Brendan Buckley; J Wouter Jukema; Rudi G J Westendorp; James Shepherd
The incidence and risk factors for new onset atrial fibrillation in the PROSPER study.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011;13(5):634-9.
2010: Bo Fan; Ying Lu; Harry K Genant; Thomas Fuerst; James Shepherd
Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems?
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(7):1227-36.
2010: David Preiss; Paul Welsh; Heather M Murray; James Shepherd; Chris Packard; Peter Macfarlane; Stuart M Cobbe; Ian Ford; Naveed Sattar
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up.
European heart journal 2010;31(10):1230-6.
2010: Muriel J Caslake; Chris J Packard; Michele Robertson; Josephine Cooney; Jeanenne J Nelson; Ian Ford; Allan Gaw; J Wouter Jukema; Peter W Macfarlane; David J Stott; James Shepherd
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Atherosclerosis 2010;210(1):28-34.
2010: John C LaRosa; Prakash C Deedwania; James Shepherd; Nanette K Wenger; Heiner Greten; David A DeMicco; Andrei Breazna
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
The American journal of cardiology 2010;105(3):283-7.
2010: Paul Welsh; Eliana Polisecki; Michele Robertson; Sabine Jahn; Brendan M Buckley; Anton J M de Craen; Ian Ford; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G J Westendorp; James Shepherd; Aroon D Hingorani; George Davey Smith; Ernst Schaefer; Naveed Sattar
Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach.
The Journal of clinical endocrinology and metabolism 2010;95(1):93-9.
2009: Naveed Sattar; Heather M Murray; Paul Welsh; Gerard J Blauw; Brendan M Buckley; Stuart Cobbe; Anton J M de Craen; GD Lowe; J Wouter Jukema; Peter W Macfarlane; Michael B. Murphy; David J Stott; Rudi G J Westendorp; James Shepherd; Ian Ford; Chris J Packard
Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?
PLoS medicine 2009;6(6):e1000099.
2009: Naveed Sattar; Heather M Murray; P Welsh; Gerard J Blauw; Brendan M Buckley; Anton J M de Craen; Ian Ford; Nita G Forouhi; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Michael B. Murphy; Chris J Packard; David J Stott; R G J Westendorp; James Shepherd
Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly.
Diabetologia 2009;52(2):235-9.
2009: Paul Welsh; Heather M Murray; Brendan M Buckley; Anton J M de Craen; Ian Ford; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G J Westendorp; James Shepherd; Naveed Sattar
Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population.
Diabetes care 2009;32(2):308-10.
2009: Ian Ford; Vladimir Bezlyak; David J Stott; Naveed Sattar; Chris J Packard; Ivan Perry; Brendan M Buckley; J Wouter Jukema; Anton J M de Craen; Rudi G J Westendorp; James Shepherd
Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis.
PLoS medicine 2009;6(1):e16.
2008: Stella Trompet; J Wouter Jukema; Ian Ford; James Shepherd; Jacobijn Gussekloo; Brendan M Buckley; Rudi G J Westendorp; Anton J M de Craen
Statins and blood pressure.
Archives of internal medicine 2008;168(21):2383.
2008: James Shepherd; John P Kastelein; Vera A Bittner; Rafael Carmena; Prakash C Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea L Zuckerman; Nanette K Wenger
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Mayo Clinic proceedings. Mayo Clinic 2008;83(8):870-9.
2008: S Trompet; Anton J M de Craen; P Eline Slagboom; James Shepherd; Gerard J Blauw; Michael B. Murphy; E L E M Bollen; Brendan M Buckley; Ian Ford; Allan Gaw; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G J Westendorp; J Wouter Jukema
Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study.
Experimental gerontology 2008;43(8):801-5.
2008: Naveed Sattar; Alex McConnachie; A Gerald Shaper; Gerard J Blauw; Brendan M Buckley; Anton J M de Craen; Ian Ford; Nita G Forouhi; Dilys J Freeman; J Wouter Jukema; Lucy Lennon; Peter W Macfarlane; Michael B. Murphy; Chris J Packard; David J Stott; Rudi G J Westendorp; Peter H Whincup; James Shepherd; S Goya Wannamethee
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies.
Lancet 2008;371(9628):1927-35.
2008: Sanjiv J Shah; David D Waters; Philip Barter; John J P Kastelein; James Shepherd; Nanette K Wenger; David A DeMicco; Andrei Breazna; John C LaRosa
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Journal of the American College of Cardiology 2008;51(20):1938-43.
2008: James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Journal of the American College of Cardiology 2008;51(15):1448-54.
2008: James Shepherd
Monotherapy vs combination therapy for dyslipidemia in the elderly.
The American journal of geriatric cardiology 2008;17(2):108-13.
2007: Chris J Packard; Rudi G J Westendorp; David J Stott; Muriel J Caslake; Heather M Murray; James Shepherd; Gerard J Blauw; Michael B. Murphy; E L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; Jelle Jolles; Ivan J Perry; Brian J Sweeney; Cillian Twomey
Association between apolipoprotein E4 and cognitive decline in elderly adults.
Journal of the American Geriatrics Society 2007;55(11):1777-85.
2007: James Shepherd; John J P Kastelein; Vera Bittner; Prakash Deedwania; Andrei Breazna; Stephen Dobson; Daniel J Wilson; Andrea Zuckerman; Nanette K Wenger
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Clinical journal of the American Society of Nephrology : CJASN 2007;2(6):1131-9.
2007: Ian Ford; Heather Murray; Chris J Packard; James Shepherd; Peter W Macfarlane; Stuart M Cobbe
Long-term follow-up of the West of Scotland Coronary Prevention Study.
The New England journal of medicine 2007;357(15):1477-86.
2007: S Trompet; Douwe Pons; Anton J M de Craen; P Eline Slagboom; James Shepherd; Gerard J Blauw; Michael B. Murphy; Stuart M Cobbe; E L E M Bollen; Brendan M Buckley; Ian Ford; Michael Hyland; Allan Gaw; Peter W Macfarlane; Chris J Packard; John Norrie; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp; J Wouter Jukema
Genetic variation in the interleukin-10 gene promoter and risk of coronary and cerebrovascular events: the PROSPER study.
Annals of the New York Academy of Sciences 2007;1100():189-98.
2007: Naveed Sattar; Alex McConnachie; Ian Ford; Allan Gaw; Stephen J Cleland; Nita G Forouhi; Peter McFarlane; James Shepherd; Stuart M Cobbe; Chris J Packard
Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor.
Diabetes 2007;56(4):984-91.
2007: Naveed Sattar; Heather M Murray; Alex McConnachie; Gerard J Blauw; E L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; Michael B. Murphy; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp; James Shepherd
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Circulation 2007;115(8):981-9.
2007: James Shepherd; Donald G Vidt; Elinor Miller; Susan Harris; James Blasetto
Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Cardiology 2007;107(4):433-43.
2006: Prakash Deedwania; Philip J Barter; Rafael Carmena; Jean-Charles Fruchart; Scott M Grundy; Steven M Haffner; John J P Kastelein; John C LaRosa; Holly Schachner; James Shepherd; David D Waters
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Lancet 2006;368(9539):919-28.
2006: James Shepherd; Philip J Barter; Rafael Carmena; Prakash Deedwania; Jean-Charles Fruchart; Steven M Haffner; Judith Hsia; Andrei Breazna; John C LaRosa; Scott Grundy; David Waters
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Diabetes care 2006;29(6):1220-6.
2005: Chris J Packard; Ian Ford; Michele Robertson; James Shepherd; Gerard J Blauw; Michael B. Murphy; E L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Circulation 2005;112(20):3058-65.
2005: James Shepherd
Special report: Highlights of the 75th European Atherosclerosis Society congress.
Atherosclerosis 2005;181(2):S1-S7.
2005: John C LaRosa; Scott M Grundy; David D Waters; Charles L Shear; Philip J Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
The New England journal of medicine 2005;352(14):1425-35.
2005: S Matthijs Boekholdt; Frank M Sacks; J Wouter Jukema; James Shepherd; Dilys J Freeman; Alex D McMahon; F Cambien; V Nicaud; Greetje J de Grooth; P J Talmud; S E Humphries; George J Miller; Gudny Eiriksdottir; Vilmundur Gudnason; Heikki Kauma; Sakari Kakko; Markku Savolainen; Marcello Arca; Anna Montali; S Liu; H J Lanz; Aeilko H Zwinderman; Jan Albert Kuivenhoven; J J P Kastelein
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Circulation 2005;111(3):278-87.
2004: Naveed Sattar; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Adrian Stanley; Ewan Forrest; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.
Diabetes 2004;53(11):2855-60.
2004: James Shepherd; Donald B Hunninghake; Philip Barter; James M McKenney; Howard G Hutchinson
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Atherosclerosis. Supplements 2004;5(3):115-23.
2004: James Shepherd; Donald B Hunninghake; Evan A Stein; John J P Kastelein; Susan Harris; John Pears; Howard G Hutchinson
Safety of rosuvastatin.
The American journal of cardiology 2004;94(7):882-8.
2004: James Shepherd
A prospective study of pravastatin in the elderly at risk: new hope for older persons.
The American journal of geriatric cardiology 2004;13(3 Suppl 1):17-24.
2004: James Shepherd
Statins for primary prevention: strategic options to save lives and money.
Journal of the Royal Society of Medicine 2004;97(2):66-71.
2004: W E Feeman; Naveed Sattar; Denis St J OReilly; Chris J Packard; James Shepherd; Allan Gaw; Peter W Macfarlane; Stuart M Cobbe; Olga Scherbakova; Ian Ford; Steven M Haffner; Chris Isles
Metabolic syndrome and diabetes mellitus.
Circulation 2004;109(3):E23.
2003: James Shepherd
Preventing the next event in the elderly: the PROSPER perspective.
Atherosclerosis. Supplements 2003;4(5):17-22.
2003: James Shepherd
Statins: putting the benefit/risk into perspective.
International journal of clinical practice. Supplement 2003;(137):27-33.
2003: Naveed Sattar; Allan Gaw; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Steven M Haffner; Chris Isles; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Circulation 2003;108(4):414-9.
2003: James Shepherd; Donald B Hunninghake; Philip Barter; James M McKenney; Howard G Hutchinson
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
The American journal of cardiology 2003;91(5A):11C-17C; discussion 17C-19C.
2002: James Shepherd; Gerard J Blauw; Michael B. Murphy; E L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Lancet 2002;360(9346):1623-30.
2002: James Shepherd
Diabetes in tomorrow's world: dark clouds do have silver linings.
Diabetes, obesity & metabolism 2002;4(6):351-5.
2002: Leanne Streja; Chris J Packard; James Shepherd; Stuart M Cobbe; Ian Ford
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).
The American journal of cardiology 2002;90(7):731-6.
2002: Peter Houx; James Shepherd; Gerard J Blauw; Michael B. Murphy; Ian Ford; E L E M Bollen; Brendan M Buckley; David J Stott; W Jukema; Michael Hyland; Allan Gaw; John Norrie; Adriaan M Kamper; Ivan J Perry; Peter W Macfarlane; A Edo Meinders; Brian J Sweeney; Chris J Packard; Cillian Twomey; Stuart M Cobbe; Rudi G J Westendorp
Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk.
Journal of neurology, neurosurgery, and psychiatry 2002;73(4):385-9.
2002: Lorne F Forster; Grace Stewart; Dorothy Bedford; James P Stewart; Elizabeth Rogers; James Shepherd; Chris J Packard; Muriel J Caslake
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Atherosclerosis 2002;164(1):129-45.
2002: James Shepherd
Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs.
Lancet 2002;359(9325):2271-3.
2002: James Shepherd; Philip Barter
Lipid-lowering--translating evidence into benefits.
Atherosclerosis. Supplements 2002;2(4):1-3.
2002: James Shepherd; A Gaw
The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2002;11 Suppl 2():17-30.
2001: A M Wallace; Alex D McMahon; Chris J Packard; A Kelly; James Shepherd; Allan Gaw; Naveed Sattar
Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).
Circulation 2001;104(25):3052-6.
2001: Gerard J Blauw; James Shepherd; Michael B. Murphy
Dementia and statins. PROSPER study group.
Lancet 2001;357(9259):881.
2001: Dilys J Freeman; John Norrie; Naveed Sattar; R D Neely; Stuart M Cobbe; Ian Ford; Chris Isles; A R Lorimer; Peter W Macfarlane; J H McKillop; Chris J Packard; James Shepherd; Allan Gaw
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
Circulation 2001;103(3):357-62.
2000: G Lowe; Ann Rumley; John Norrie; Ian Ford; James Shepherd; Stuart M Cobbe; P Macfarlane; Chris J Packard
Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
Thrombosis and haemostasis 2000;84(4):553-8.
2000: C Packard; Muriel J Caslake; James Shepherd
The role of small, dense low density lipoprotein (LDL): a new look.
International journal of cardiology 2000;74 Suppl 1():S17-22.
2000: Chris J Packard; Thomas Demant; James P Stewart; Dorothy Bedford; Muriel J Caslake; G Schwertfeger; Andrea Bedynek; James Shepherd; Dietrich Seidel
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
Journal of lipid research 2000;41(2):305-18.
1999: H A Ardern; Gregory Martin Benson; Keith Suckling; Muriel J Caslake; James Shepherd; Chris J Packard
Apolipoprotein B overproduction by the perfused liver of the St. Thomas' mixed hyperlipidemic (SMHL) rabbit.
Journal of lipid research 1999;40(12):2234-43.
1999: James Shepherd; Gerard J Blauw; Michael B. Murphy; Stuart M Cobbe; E L E M Bollen; Brendan M Buckley; Ian Ford; J Wouter Jukema; Michael Hyland; Allan Gaw; A Margot Lagaay; Ivan J Perry; Peter W Macfarlane; A Edo Meinders; Brian J Sweeney; Chris J Packard; Rudi G J Westendorp; Cillian Twomey; David J Stott
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.
The American journal of cardiology 1999;84(10):1192-7.
1999: James Shepherd
From best evidence to best practice - what are the obstacles?
Atherosclerosis 1999;147 Suppl 1():S45-51.
1999: JS Millar; V Anber; James Shepherd; Chris J Packard
Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
Atherosclerosis 1999;145(2):253-60.
1999: Naveed Sattar; Ian A Greer; A Rumley; G Stewart; James Shepherd; Chris J Packard; G D Lowe
A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy.
Thrombosis and haemostasis 1999;81(1):71-5.
1999: Naveed Sattar; Ian A Greer; P J Galloway; C J Packard; James Shepherd; T Kelly; A Mathers
Lipid and lipoprotein concentrations in pregnancies complicated by intrauterine growth restriction.
The Journal of clinical endocrinology and metabolism 1999;84(1):128-30.
1998: James Shepherd
Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
The American journal of cardiology 1998;82(10B):57T-59T.
1998: James Shepherd
A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study.
Atherosclerosis 1998;139(2):223-9.
1998: Dilys J Freeman; Muriel J Caslake; B A Griffin; J Hinnie; C E Tan; T D Watson; Chris J Packard; James Shepherd
The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma.
European journal of clinical investigation 1998;28(7):584-91.
1998: James Shepherd; A G Olsson; F M Sacks; D M Black; D G Orloff; D W Bilheimer
Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
The American journal of cardiology 1998;81(8A):88F-94F.
1998: James Shepherd
International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. Heart European Leaders Panel.
Atherosclerosis 1998;137 Suppl():S117-23.
1997: Chris J Packard; James Shepherd
Lipoprotein heterogeneity and apolipoprotein B metabolism.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(12):3542-56.
1997: V Anber; JS Millar; M McConnell; James Shepherd; Chris J Packard
Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2507-14.
1997: Naveed Sattar; Ian A Greer; J Louden; G Lindsay; M McConnell; James Shepherd; Chris J Packard
Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein.
The Journal of clinical endocrinology and metabolism 1997;82(8):2483-91.
1997: James Shepherd
Tomorrow's world: atherosclerosis in the year 2000.
The Netherlands journal of medicine 1997;50(5):221-7.
1997: Naveed Sattar; A Bendomir; C Berry; James Shepherd; Ian A Greer; Chris J Packard
Lipoprotein subfraction concentrations in preeclampsia: pathogenic parallels to atherosclerosis.
Obstetrics and gynecology 1997;89(3):403-8.